Clinical trials: DNA Damage, active
Biliary Tract Cancer, DNA Damage Repair Deficiency
Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy
First-line gemcitabine plus cisplatin chemotherapy is the standard first-line treatment for unresectable or metastatic advanced biliary tract cancer and the optimal duration of the treatment is not mentioned in current clinical…
- Trial name
- OPTIMUM (NCT05222971)
- Testing
- Durvalumab, Olaparib
- Where
- South Korea
- Volunteers
- 62 people
- Sponsor
- Asan Medical Center
Skin Cancer, Heat Tolerance
Title: ICARUS - Psycho-physiological Profiling of Low and High Heat-resilient Individuals
The escalating environmental heat-stress associated with global warming is a societal challenge with large and potential harmful consequences for humans.
- Conditions
- Skin Cancer, Heat Tolerance, Heat-related Illness, Hyperthermia
- Trial name
- ICARUS (NCT07510061)
- Testing
- Controlled Heat and Ultraviolet Radiation Exposure Protocol
- Where
- 2 sites in Denmark, Greece
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Thessaly
Advanced Solid Tumor, Metastatic Solid Tumor
Study of LP-184 in Patients With Advanced Solid Tumors
The primary objective of this study is to evaluate the safety, tolerability, MTD and RP2D of LP-184 in patients with advanced solid tumors who have relapsed from or are refractory to standard therapy or for whom no standard…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, GBM, TNBC - Triple-Negative Breast Cancer
- Trial name
- NCT05933265
- Testing
- LP-184, Olaparib, Nivolumab & Ipilimumab
- Where
- 7 sites in United States
- Volunteers
- 64 people
- Sponsor
- Lantern Pharma Inc.
DNA Damage
sperDNA Fragmentation a a Predictor for Outcome After Varicocelectomy,m
Varicocele is often associated with infertility and reduction in sperm quality, and it is one of the most common causes of reversible male infertility.
- Trial name
- NCT07144891
- Testing
- Sperm DNA fragmentation
- Volunteers
- 1 people
- Sponsor
- Assiut University
Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer
Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents
This is a modular, phase I/ phase 1 b, open-label, multicentre study of ceralasertib administered orally in combination with cytotoxic chemotherapy regimens and/or novel anti-cancer agents, to patients with advanced malignancies.
- Trial name
- NCT02264678
- Testing
- Administration of ceralasertib, Administration of ceralasertib in combination with olaparib, Administation of ceralasertib in combination with durvalumab
- Where
- 28 sites in United States, France and 2 more
- Volunteers
- 358 people
- Sponsor
- AstraZeneca
Aging, Obesity
Obesity and Aging: Impacts of Nutritional Counseling and Physical Exercise on Telomeres and Senescence Parameters
The study will involve 80 elderly women, 40 eutrophic and 40 obese, divided into four groups, each with n=20. 1) Eutrophic Group (EG) undergoing only nutritional counseling (NC), 2) Eutrophic Group with NC and combined training…
- Conditions
- Aging, Obesity, Nutrition, Exercise
- Trial name
- NCT07479940
- Testing
- Combined Training, Nutritional Counseling
- Where
- Brazil
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo
Prostate Cancer
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
The purpose of the study is to evaluate the safety and efficacy of talazoparib in combination with enzalutamide compared with placebo in combination with enzalutamide in participants with DDR-deficient mCSPC.
- Trial name
- NCT04821622
- Testing
- talazoparib plus enzalutamide
- Where
- 312 sites in United States, Argentina and 25 more
- Volunteers
- 599 people
- Sponsor
- Pfizer
Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer
Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes
The usual approach for most patients who are not in a study is treatment with docetaxel. This study is being done to answer the following question: Can the chance of prostate cancer growing or spreading be lowered by adding a…
- Trial name
- OPTION-DDR (NCT06439225)
- Testing
- Docetaxel, Carboplatin
- Where
- 14 sites in Canada
- Volunteers
- 236 people
- Sponsor
- Canadian Cancer Trials Group
Sarcoma,Soft Tissue, Sarcoma Uterus
A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA
The purpose of this study is to test whether the study drug, niraparib, is effective against unresectable and/or metastatic soft tissue sarcoma with DDR mutations.
- Trial name
- NCT05515575
- Testing
- Niraparib
- Where
- 7 sites in United States
- Volunteers
- 8 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Head and Neck Squamous Cell Carcinoma (HNSCC)
Molecular Imaging of DNA Damage Response by [18F]-Olaparib PET
This is a single-centre, non-randomized, two-stage design, proof-of-concept study evaluating the radiolabelled PARP inhibitor [18F]-olaparib als potential tracer for imaging of tumour PARP expression by PET.
- Trial name
- [18F]-olaparib (NCT06482307)
- Testing
- [18F]-olaparib PET scan
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- University Medical Center Groningen
Breast Cancer
A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer
This study will test any good and bad effects of combining the study drugs pembrolizumab and olaparib, given before the standard surgical procedure, to treat TNBC or HR+ HER2- breast cancers.
- Trial name
- NCT05203445
- Testing
- Olaparib, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 6 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Diet, Healthy, Body Weight
Diet-Induced Changes in GEnetic Material
This is a pilot study in 10 men to test the hypothesis that perturbations in substrate flux and the circulating metabolic and pro-inflammatory milieus during a high-fat diet paradigm will modulate DNA methylation of genes in…
- Conditions
- Diet, Healthy, Body Weight, Metabolic Disturbance
- Trial name
- DIG 'EM (NCT06252922)
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Pennington Biomedical Research Center
Coronary Arterial Disease (CAD)
The Effect of Cardiac Rehabilitation on Oxidative DNA Damage and Inflammation in Patients With Coronary Artery Disease
The objective of this study was to determine the levels of 8-hydroxy-2'-deoxyguanosine (8-OHdG), an indicator of oxidative stress, and to demonstrate oxidative DNA damage in cardiac rehabilitation treatment in patients with…
- Trial name
- NCT06867926
- Testing
- Cardiac rehabilitation
- Where
- Turkey (Türkiye)
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- TC Erciyes University
Breast Neoplasm, Triple Negative Breast Cancer (TNBC)
PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer
PHOENIX is a window of opportunity (WOP), open-label, multi-centre, phase IIa trial comprising multiple non-comparative treatment cohorts with patient allocation via minimisation (cohorts A-D) or allocation according to HRD and…
- Conditions
- Breast Neoplasm, Triple Negative Breast Cancer (TNBC), HRD
- Trial name
- PHOENIX (NCT03740893)
- Testing
- AZD6738, Olaparib, Durvalumab
- Where
- 6 sites in United Kingdom
- Volunteers
- 119 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Solid Cancers, BRCA Mutation
A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway
The primary objective of the study is to evaluate the safety, tolerability, PK, PD, and prilimary efficacy of a PARG inhibitor DAT-2645 in patients with advanced/metastatic solid tumors harboring BRCA1/2 loss of function…
- Conditions
- Solid Cancers, BRCA Mutation, HRD Cancer, Breast Cancer
- Trial name
- NCT06614751
- Testing
- DAT-2645 tablet
- Where
- 2 sites in China
- Volunteers
- 112 people
- Sponsor
- Danatlas Pharmaceuticals Co., Ltd
Healthy Adult Participants
Multilevel Exercise Response in Rowers
This observational study aims to evaluate multilevel physiological, molecular, metabolic, intestinal, immunological, and psychophysiological responses to rowing-specific exercise in elite rowers.
- Trial name
- NCT07613619
- Testing
- 2000-m rowing ergometer test, 6000-m rowing ergometer test
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Poznan University of Physical Education
Prostate Cancer, Radiotherapy Side Effects
Using Breath, Cell Free DNA and Image Analysis to PRedIct Normal TissUe and Tumour Response During Prostate Cancer SBRT
Personalisation of radiotherapy dose based on real-time assessments of normal tissue and tumour response would maximise cure and minimise treatment related toxicity.
- Conditions
- Prostate Cancer, Radiotherapy Side Effects, Volatile Organic Compounds, DNA Damage
- Trial name
- PRINToUT (NCT04081428)
- Testing
- Stereotactic Body Radiotherapy
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- NHS Lothian
Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors
This phase I/II trial studies the side effects and best dose of avelumab with M6620 in treating patients with deoxyribonucleic acid (DNA) damage repair (DDR) deficient solid tumors that have spread to other places in the body…
- Conditions
- Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
- Trial name
- NCT04266912
- Testing
- Avelumab, Berzosertib
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- M.D. Anderson Cancer Center
Adrenocortical Carcinoma (ACC), Recurrent Adrenocortical Carcinoma (ACC)
Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma
Background: Adrenocortical carcinoma (ACC) is a rare cancer of the adrenal glands. ACC often returns after tumors are removed with surgery. Less than 35% of people with ACC survive 5 years after diagnosis.
- Conditions
- Adrenocortical Carcinoma (ACC), Recurrent Adrenocortical Carcinoma (ACC), Recurrent Abdominal Adrenocortical Carcinoma (ACC), Carcinoma, Adrenocortical
- Trial name
- NCT06487481
- Testing
- Surgical resection, Preoperative RT
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
Infiltrating Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma
Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations
This phase II trial studies how well gemcitabine hydrochloride and cisplatin work in treating participants with invasive bladder urothelial cancer.
- Conditions
- Infiltrating Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma
- Trial name
- NCT03609216
- Testing
- Gemcitabine Hydrochloride, Cisplatin, Pegfilgrastim
- Where
- 424 sites in United States
- Volunteers
- 237 people
- Sponsor
- Alliance for Clinical Trials in Oncology